MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$218,250K
Net Income
$78,235K
Net Profit Margin
35.85%
EPS
$0.3
Unit: Thousand (K) dollars
Revenue Breakdown
Product
License And Other Revenues
Revenue Breakdown
ORLADEYO
License Revenue And Other Income...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
218,250
156,413
406,555
159,395
Cost of product sales
3,840
5,377
9,522
2,187
Acquired in-process research and development
0
697,761
-
-
Research and development
51,969
60,319
40,867
44,603
Selling, general and administrative
63,976
94,554
95,781
83,014
Total operating expenses
119,785
858,011
146,170
129,804
Income (loss) from operations
98,465
-701,598
260,385
29,591
Interest income
2,434
2,256
2,890
2,238
Interest expense
21,712
19,779
14,135
19,661
Foreign currency gains (losses), net
27
-225
-125
35
Loss on extinguishment of debt
0
-
-5,087*
-2,740
Other income
-
-
4,089*
2,667
Other income (expense), net
260
-1,462
-
-
Total other expense, net
-18,991
-19,210
-12,368
-17,461
Income (loss) before income taxes
79,474
-720,808
248,017
12,130
Income tax expense
1,079
1,004
2,172
-769
Net income (loss)
78,395
-721,812
245,845
12,899
Foreign currency translation adjustment
-27
-62
-1,219
-523
Unrealized gain on available for sale investments
-133
-344
117
17
Total other comprehensive (loss) income
-160
-406
-1,102
-506
Net comprehensive income (loss)
78,235
-722,218
244,743
12,393
Basic EPS
0.31
-2.98
1.16
0.06
Diluted EPS
0.3
-2.98
1.116
0.06
Basic Average Shares
254,481,000
242,258,000
210,995,000
210,176,000
Diluted Average Shares
265,165,000
242,258,000
219,292,000
219,885,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Product
$157,513K
(-3.03%↓ Y/Y)
License And Other
Revenues
$60,737K
Total revenues
$218,250K
(33.61%↑ Y/Y)
Income (loss) from
operations
$98,465K
(230.57%↑ Y/Y)
Total operating
expenses
$119,785K
(-10.32%↓ Y/Y)
Income (loss) before
income taxes
$79,474K
(1125.32%↑ Y/Y)
Total other expense,
net
-$18,991K
(18.49%↑ Y/Y)
Interest income
$2,434K
(-3.26%↓ Y/Y)
Other income
(expense), net
$260K
Foreign currency gains
(losses), net
$27K
(142.86%↑ Y/Y)
Selling, general and
administrative
$63,976K
(-26.79%↓ Y/Y)
Research and development
$51,969K
(19.78%↑ Y/Y)
Cost of product sales
$3,840K
(37.24%↑ Y/Y)
Net income (loss)
$78,395K
(1441.69%↑ Y/Y)
Income tax expense
$1,079K
(-22.98%↓ Y/Y)
Interest expense
$21,712K
(0.60%↑ Y/Y)
Net comprehensive
income (loss)
$78,235K
(1297.30%↑ Y/Y)
Total other
comprehensive (loss) income
-$160K
(-131.13%↓ Y/Y)
Unrealized gain on
available for sale...
-$133K
(29.26%↑ Y/Y)
Foreign currency
translation adjustment
-$27K
(-103.85%↓ Y/Y)
Buy us a coffee
BIOCRYST PHARMACEUTICALS INC (BCRX)
BIOCRYST PHARMACEUTICALS INC (BCRX)